Published in J Virus Erad on January 01, 2016
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2015) 9.40
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Global epidemiology of HIV infection in men who have sex with men. Lancet (2012) 9.18
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol (2008) 5.17
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Toward an AIDS vaccine. Science (2008) 4.83
Cellular immune responses to HIV. Nature (2001) 4.61
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature (2014) 3.73
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med (2010) 3.44
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
A formalin-inactivated whole SIV vaccine confers protection in macaques. Science (1989) 3.37
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet (1992) 2.60
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature (2015) 2.56
Systems vaccinology. Immunity (2010) 2.36
Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell (2014) 2.01
Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol (1995) 1.63
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol (1996) 1.59
Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med (2013) 1.59
Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med (2012) 1.56
Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 1.50
Heterogeneity of HIV-1 and HIV-2. AIDS (1995) 1.41
Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med (1992) 1.38
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol (2013) 1.31
HIV-1 vaccines and adaptive trial designs. Sci Transl Med (2011) 1.21
The prime-boost concept applied to HIV preventive vaccines. AIDS (1997) 1.20
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18
Determinants of protection among HIV‐exposed seronegative persons: an overview. J Infect Dis (2010) 1.13
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol (2014) 1.04
New observations on cellular immune responses to HIV and T-cell epitopes. AIDS (1997) 1.02
HIV controllers: a genetically determined or inducible phenotype? Immunol Rev (2013) 0.98
Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol (2014) 0.97
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis (2009) 0.96
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS (2013) 0.96
Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol (2014) 0.93
Is an HIV vaccine possible? Nat Med (1999) 0.93
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93
In vivo protection by broadly neutralizing HIV antibodies. Trends Microbiol (2014) 0.90
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One (2015) 0.82
Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clin Trials (2015) 0.82
Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo. PLoS One (2015) 0.77